Clinical Holds in Early Oncology Drug Development
Snyder, A.; De Alwis, D.; Goonewardene, A.; Hegde, P.
Show abstract
Clinical holds in oncology are necessary to safeguard patients. Researchers are alerted to holds by news sources, but a systematic evaluation of clinical holds in early oncology drug development is lacking. Analysis of publicly disclosed clinical holds in oncology from 2016-2021 identified 39 holds. The majority (n=29) were for toxicity-related reasons, with fewer for chemistry, manufacturing and controls (CMC) (n=7) or other reasons (n=3). Toxicity-related holds took a median of 74 days till resolution, whereas chemistry, manufacturing and controls (CMC)-related holds took a median of 108 days to resolve. Acknowledging the limited sample size and scope of stock market conditions, toxicity-related clinical holds impacted the market value of small/medium sized biotechs by a median of -15%, which is far more than large biopharma (median 0%). These data suggest that toxicity-related clinical holds are common in early oncology and can have a more detrimental impact on small/medium sized biotech sponsors, the latter of which could have substantial financial repercussions, particularly in "biotech bear markets" where public investing in the sector has fallen out of favor (as in 2021-2022).
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial 89%
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis 89%
- The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown 89%
Similar papers in this journal
- An Evaluation of the Efficacy of Preclinical Models of Lung Cancer Drugs 90%
- Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes 90%
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 89%
Similar papers in this journal
- A three gene signature predicts response to selinexor in multiple myeloma 89%
- An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology 89%
- Clinical Opportunities For Germline Pharmacogenetics And Management Of Drug-Drug Interactions In Patients With Advanced Solid Cancers 89%
Similar papers in this journal
- Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease- the impact of diagnosis and cancer-directed therapies 90%
- AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes 89%
- Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.